Financial Report

PolyPeptide Half-year Report 2023

Interim consolidated income statement

1 January - 30 June (unaudited)

kEUR

Note

H1 2023

H1 2022

 

 

 

 

Revenue

4

131,834

133,656

Other operating income

 

1,544

954

Total income

 

133,378

134,610

 

 

 

 

Cost of sales

5

-144,006

-96,776

Gross profit / (loss)

 

-10,628

37,834

 

 

 

 

Marketing and sales expenses

 

-1,993

-2,589

Research expenses

 

-746

-656

General and administrative expenses

5

-21,097

-19,107

Total operating expenses

 

-23,836

-22,352

 

 

 

 

Operating result (EBIT)

 

-34,464

15,482

 

 

 

 

Financial income

 

21

4

Financial expenses

 

-4,784

-2,645

Total financial result

 

-4,763

-2,641

 

 

 

 

Result before income taxes

 

-39,227

12,841

 

 

 

 

Income tax

 

4,961

-2,594

Result for the period

 

-34,266

10,247

 

 

 

 

Attributable to shareholders of PolyPeptide Group AG

 

-34,266

10,247

 

 

 

 

Earnings per share in EUR, basic

 

-1.04

0.31

Earnings per share in EUR, diluted

 

-1.04

0.31